| African Americans |  |  |  |  |
---|---|---|---|---|---|
 | All | non-MSI-H | MSI-H | Odds Ratio (95% CI) | P |
Number of patients | 95 | 66 (69)a | 29 (31)a | Â | Â |
Mean Age | 65.7+15.0 - | 65.2+14.0 - | 65.9+17.5 - | Â | 0.84 |
Gender | Â | Â | Â | Â | 0.39 |
   Female | 56 (59) | 37 (57) | 19 (66) | 1 |  |
   Male | 39 (41) | 29 (43) | 10 (34) | 0.67(0.27–1.67) |  |
Site | Â | Â | Â | Â | 0.47 |
   Distal | 38 (40) | 28 (43) | 10 (34) | 1 |  |
   Proximal | 57 (60) | 38 (57) | 19 (66) | 0.71(0.29–1.77) |  |
Mucin Production | 95 | Â | Â | Â | 0.15 |
   None | 68 (72) | 51(77) | 17(58) | 1 |  |
   < 50% | 15 (15) | 9 (14) | 6 (21) | 2.0(0.62–6.44) |  |
   > 50% | 12 (13) | 6 (9) | 6(21) | 3.0(0.85–10.55) |  |
Differentiation | 90 | Â | Â | Â | 0.47 |
   Well | 3 (3) | 2 (3) | 1 (3) | 1 |  |
   Moderate | 71 (79) | 51 (83) | 20 (72) | 0.64(0.5–8.62) |  |
   Poor | 16 (18) | 9 (14) | 7 (25) | 0.5(0.17–1.54) |  |
Stage | 92 | Â | Â | Â | 0.59 |
   Stage 1 | 8 (9) | 7 (11) | 1 (3) | 1 |  |
   Stage 2 | 37 (40) | 24 (38) | 13 (45) | 0.67(0.09–4.93) |  |
   Stage 3 | 35 (38) | 23 (37) | 12 (41) | 1.08(0.27–4.29) |  |
   Stage 4 | 12 (13) | 9 (14) | 3 (11) | 0.8(0.2–3.27) |  |
BRAF | 82 | Â | Â | Â | 0.00 |
   wild type | 74 (90) | 59 (98) | 15 (68) |  |  |
   V600E | 8 (10) | 1 (2) | 7 (32) | 27.5(3.1–241.3) |  |
hMLH1 methylation (MSP) | 70 | Â | Â | Â | 0.33 |
   Unmethylation | 4 (6) | 2 (4) | 2 (10) | 1 |  |
   Methylation | 66 (94) | 48 (96) | 18 (90) | 0.38(0.5–2.87) |  |
p16 methylation (MSP) | 47 | Â | Â | Â | 0.37 |
   Unmethylation | 28 (60) | 14 (54) | 14 (67) | 1 |  |
   Methylation | 19 (40) | 12 (46) | 7 (33) | 0.58(0.18–1.92) |  |
hMLH1 expression by IHC | 76 | Â | Â | Â | 0.00 |
   Normal | 50 (65) | 45 (83) | 5 (23) | 1 |  |
   Negative | 26 (35) | 9 (17) | 17 (77) | 16.67(5–50) |  |
hMSH2 expression by IHC | 74 | Â | Â | Â | 0.29 |
   Normal | 66 (89) | 46 (87) | 20 (95) | 1 |  |
   Negative | 8 (11) | 7 (13) | 1 (5) | 0.33(0.04–2.86) |  |